Description
POLMAWAR contains Polmacoxib, a selective cyclooxygenase-2 (COX-2) inhibitor with additional carbonic anhydrase inhibitory activity. It provides effective relief from pain and inflammation associated with osteoarthritis and other musculoskeletal disorders, with a reduced risk of gastrointestinal adverse effects compared to conventional NSAIDs.
Polmacoxib (2 mg)
-
Selectively inhibits COX-2 enzyme, reducing prostaglandin synthesis at sites of inflammation.
-
Spares COX-1 activity, thereby minimizing gastrointestinal mucosal damage.
-
Dual mechanism with mild carbonic anhydrase inhibition may enhance safety profile.
-
Provides analgesic, anti-inflammatory, and antipyretic effects.
Indications
POLMAWAR is indicated for
-
Osteoarthritis (symptomatic relief of pain and inflammation)
-
Chronic joint disorders requiring long-term NSAID therapy
-
Musculoskeletal pain associated with inflammation
